FIELD: medicine.
SUBSTANCE: group of inventions relates to therapy and endocrinology, and to the use of long-acting GLP-1 peptides for the treatment of obesity. For this, 0.7 mg semaglutide is administrated per week as a monotherapy.
EFFECT: this provides the most effective weight loss in comparison with the action of other GLP-1 receptor agonists.
22 cl, 5 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ACYLATED DERIVATIVE OF GLP-1 | 2019 |
|
RU2773242C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
| TREATING LIVER DISEASE OR DISORDER INVOLVING USE OF ACTRII RECEPTOR ANTAGONISTS | 2020 |
|
RU2838150C1 |
| THERAPEUTIC USE OF GLUCAGON AND ITS COMBINATION | 2019 |
|
RU2838895C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
| TOLEROGENIC DNA VACCINE | 2017 |
|
RU2752608C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING A POLYPEPTIDE | 2019 |
|
RU2777095C1 |
